Rapid Point-of-Care Testing For Sickle Cell Anemia Market Size, Share & Trends Analysis Report By Type (Lateral Flow Immunoassay, Paper-Based Rapid Diagnostics), By Technology, By Age Group, By Sector Type, By Distribution Channel, By End-use, By Region,

Rapid PoC Testing For Sickle Cell Anemia Market Summary

The global rapid point-of-care testing for sickle cell anemia market size was estimated at USD 328.69 million in 2025 and is projected to reach USD 735.35 million by 2033, growing at a CAGR of 10.91% from 2026 to 2033. The market is driven by advancements in diagnostic technology and the rising demand for accessible healthcare solutions.

POC tests provide faster, more accurate, cost-effective diagnosis, especially in resource-limited areas, a high prevalence of sickle cell anemia. These innovations enable early detection, improving patient outcomes. In addition, growing investments, partnerships with global health organizations, and expanding healthcare in developing nations are accelerating market growth and fostering widespread adoption. According to a report from the CDC in May, around 100,000 individuals in the U.S. are impacted by sickle cell anemia; over 90% of these cases are among non-Hispanic Black or African American individuals, while an estimated 3%-9% are of Hispanic or Latino descent.

Sickle cell anemia is a hereditary blood disorder characterized by the production of abnormally shaped red blood cells. These sickle-shaped cells can cause severe pain, anemia, and potential organ damage due to their tendency to block blood flow. According to the Journal of Hematology and Allied Science (JHAS), India has one of the highest reported frequencies of the sickle β-globin allele. It ranks as the second most affected country in terms of sickle β-globin thalassemia. The World Health Organization (WHO) estimates that 4.5% to 5% of the global population carries hemoglobinopathy traits. In India alone, approximately 30 million individuals are carriers, with a national prevalence of 3.3% on average. The incidence of sickle cell anemia in India varies significantly, ranging from 1% to 44% in different regions.

Global Rapid Point-of-Care Testing For Sickle Cell Anemia Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global rapid point-of-care testing for sickle cell anemia market report based type, technology, age group, sector type, end-use, distribution channel, and region:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Lateral Flow Immunoassay
• Paper-Based Rapid Diagnostics
• Others
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Hemoglobin Electrophoresis
• Polymerase Chain Reaction (PCR)
• Isothermal Amplification Assays
• Others
• Age Group Outlook (Revenue, USD Million, 2021 - 2033)
• Newborn Screening (12 months and below)
• Adult Screening (25 to 60 years)
• Other Age Groups (1 to 25 & Above 60 years)
• Sector Type Outlook (Revenue, USD Million, 2021 - 2033)
• Government Labs
• Private Labs
• Corporate Labs
• PPP (Public-Private-Partnerships)
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals & Clinics
• Diagnostics Laboratories
• Research Institutions
• Homecare Settings
• Others
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• B2B (Business-to-Business)
• B2C (Business-to-Consumer)
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
• U.S.
• Canada
• Mexico
• Europe
• UK
• Germany
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway
• Asia Pacific
• Japan
• China
• India
• Australia
• South Korea
• Thailand
• Latin America
• Brazil
• Argentina
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait

Please note The report will be delivered in 2-3 business days upon order notification. Show more